Literature DB >> 17541048

Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy.

Mary Amanda Dew1, Ellen M Whyte, Eric J Lenze, Patricia R Houck, Benoit H Mulsant, Bruce G Pollock, Jacqueline A Stack, Salem Bensasi, Charles F Reynolds.   

Abstract

OBJECTIVE: Few data are available concerning the utility of augmentation in late-life depression treatment. The authors examined likelihood, speed, and predictors of recovery in older adults receiving augmentation pharmacotherapy after inadequate response to standardized treatment with paroxetine plus interpersonal psychotherapy.
METHOD: Depression levels were monitored during open treatment in 195 adults age 70 or older. Patients were grouped by whether they required augmentation (bupropion, nortriptyline, or lithium) and compared on likelihood, time, and predictors of recovery.
RESULTS: Augmentation was required for 105 patients (53.8%) because of inadequate treatment response (N=77) or response followed by relapse (N=28). Of these patients, 69 received augmentation and 36 did not (primarily because of consent withdrawal or comorbid medical conditions). Patients receiving augmentation showed lower recovery rates than patients never requiring augmentation: recovery occurred in 50.0% of patients receiving it because of inadequate response, 66.7% of those receiving it after early relapse, and 86.7% of patients never requiring augmentation. Patients receiving augmentation because of inadequate response recovered more slowly, with modestly more side effects than other patients. Greater medical burden and anxiety predicted slower recovery.
CONCLUSIONS: Despite a lower likelihood of recovery in elderly people receiving augmentation, the recovery by over one-half of such patients suggests the value of augmentation for those able to tolerate it. Need for augmentation presages slower recovery in patients showing initial inadequate response; those requiring it after early relapse recovered more quickly. Strategies to further improve the likelihood and speed of recovery after initial treatment failure are needed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17541048     DOI: 10.1176/ajp.2007.164.6.892

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  18 in total

Review 1.  Use of antidepressants in late-life depression.

Authors:  Tarek K Rajji; Benoit H Mulsant; Francis E Lotrich; Cynthia Lokker; Charles F Reynolds
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

2.  Treating depression in older adults with dementia.

Authors:  Eric J Lenze
Journal:  J Am Geriatr Soc       Date:  2011-04       Impact factor: 5.562

Review 3.  Neuromodulation therapies for geriatric depression.

Authors:  Verònica Gálvez; Kerrie-Anne Ho; Angelo Alonzo; Donel Martin; Duncan George; Colleen K Loo
Journal:  Curr Psychiatry Rep       Date:  2015-07       Impact factor: 5.285

4.  Transdermal Nicotine for the Treatment of Mood and Cognitive Symptoms in Nonsmokers With Late-Life Depression.

Authors:  Jason A Gandelman; Hakmook Kang; Ashleigh Antal; Kimberly Albert; Brian D Boyd; Alexander C Conley; Paul Newhouse; Warren D Taylor
Journal:  J Clin Psychiatry       Date:  2018-08-28       Impact factor: 4.384

5.  Empirically derived decision trees for the treatment of late-life depression.

Authors:  Carmen Andreescu; Benoit H Mulsant; Patricia R Houck; Ellen M Whyte; Sati Mazumdar; Alexandre Y Dombrovski; Bruce G Pollock; Charles F Reynolds
Journal:  Am J Psychiatry       Date:  2008-05-01       Impact factor: 18.112

6.  Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.

Authors:  Meera Sheffrin; Henry C Driscoll; Eric J Lenze; Benoit H Mulsant; Bruce G Pollock; Mark D Miller; Meryl A Butters; Mary Amanda Dew; Charles F Reynolds
Journal:  J Clin Psychiatry       Date:  2009-02-10       Impact factor: 4.384

Review 7.  Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age.

Authors:  Henry C Driscoll; Jordan F Karp; Mary Amanda Dew; Charles F Reynolds
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

8.  [Neurobiological subtypes of geriatric depression. Their importance for diagnosis and treatment].

Authors:  M A Rapp
Journal:  Z Gerontol Geriatr       Date:  2013-02       Impact factor: 1.281

9.  Effects of lamotrigine on mood in older adults with epilepsy and co-morbid depressive symptoms: an open-label, multicentre, prospective study.

Authors:  Toufic A Fakhoury; J Mitchell Miller; Anne E Hammer; Alain Vuong
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 10.  Going beyond antidepressant monotherapy for incomplete response in nonpsychotic late-life depression: a critical review.

Authors:  Donovan T Maust; David W Oslin; Michael E Thase
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.